State Pharmacopoeia of Ukraine

Similar documents
The State Pharmacopoeia of the Russian Federation

Indian Pharmacopoeia Commission

EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines

Pharmakon drug Poiea to make Government of each country List of Pharmacopeias: British European Indian International United state.

Recognized Pharmacopoeia in Registration system

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON DISINTEGRATION TEST GENERAL CHAPTER Q4B ANNEX 5(R1)

Requirements to the Registration of Medicinal products in the Republic of Armenia

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

in the ICH Regions Table of Content Annexes to Guideline and 3. Why is Q4B necessary? Q4B Annexes? for Human Use

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

WHITE PAPER ACCESS TO GOOD QUALITY DIETARY SUPPLEMENTS

GOOD PHARMACOPOEIAL PRACTICES

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

The International Pharmacopoeia - Overview

GUIDE TO REGISTER HOMEOPATHIC PRODUCTS FOR VETERINARY USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Topics covered by the talk

Research on the Administrative Rules of APIs, Pharmaceutical Excipients and Auxiliary Materials Master File. Translation version

General concepts in the Ph. Eur.: theory and rationale

MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

Kazuhiko Mori Ministry of Health, Labour and Welfare

Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017

USP Perspective on Atypical Actives November 29, 2017

Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015

Dagmar Roth-Behrendt Vice-President of the European Parliament

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

Agenda. The current state of Pharmaceutical Excipients in Japan -JPE, JP, DMF, GAB (GMP Auditing Board)- Pharmaceutical Excipients

COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) PROGRAMME RESULTS

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

the EUROPEAN COMMISSION INITIATIVE

IPEC Japan Update. Keiji Kijima Ph.D. Feb. 6 th, 2015 Hotel Negresco Nice (France)

::Contents:: IPEC Japan Update. 1. Self-imposed Standards of Excipient GMP Self-imposed Standards of Excipient GMP 2014

Public Assessment Report for a Homeopathic Medicinal Product for Human Use

syllabus (.pdf) for Prof. McCarthy s class is also available.

Guideline on the Regulation of Therapeutic Products in New Zealand

Organic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017

Overview of USP General Chapters <476> and <1086> Prescription/Non-Prescription Stakeholder Forum October 19, 2017

Work plan for the joint CHMP/ CVMP Quality Working Party (QWP) for 2018

Review of Medicines Act 1968: informal consultation on issues relating to the PLR regime and homeopathy

Health Products Regulatory Authority IPAR. Public Assessment Report for a. Traditional Herbal Medicinal Product

The WHO International EMF Project: The road ahead

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia

SUMMARY MINUTES. of the BRITISH PHARMACOPOEIA COMMISSION

CENTRAL COUNCIL FOR RESEARCH IN HOMOEOPATHY ORGANISES

COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

SUMMARY REPORT OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 10 DECEMBER 2012 (Section General Food Law)

NEW ASPECTS IN MEDICAL DEVICES REGULATION IN RUSSIAN FEDERATION

This Administrative regulation will come into force on 1 st August 2013 and will remain so until further notice.

Application for the deletion of bevacizumab (Avastin ) on the WHO Model List of Essential Medicines

This Administrative regulation will come into force on 1 st January 2018 and will remain so until further notice. Administrative Regulation No 3/2015

DRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX

FOOD AND DRUGS AUTHORITY (FDA) GHANA

Russian Society of Cardiology: an example of a successful National Cardiac Society membership scheme

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) DRAFT (12/08) POINTS TO CONSIDER ON STABILITY TESTING OF HOMEOPATHIC MEDICINAL PRODUCTS

Guide to Registration of Homeopathic Veterinary Medicinal Products

Designing publicly funded healthcare markets Note by the Russian Federation

General Chapter/Section: <232> Elemental Impurities - Limits Expert Committee(s): General Chapters Chemical Analysis No.

Analytical method validation. Presented by Debbie Parker 4 July, 2016

EHR Developer Code of Conduct Frequently Asked Questions

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

Development of the Nation-Wide Dosimetric Monitoring Network in Ukraine

All member States were represented, except Bulgaria and Czech Republic

2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary

Meeting Report Consultation between WHO Secretariat and the Secretariat of the CBD March 2017 Montreal, Canada

This document is a preview generated by EVS

Cancer prevention and control in the context of an integrated approach

COMMISSION REGULATION (EU)

GUIDE FOR THE NEW ELECTRONIC PAYMENT SYSTEM. Version 1.0 Spanish Agency of Medicines and Medical Devices

Medical Devices. UKRAINE Magisters

REPUBLIC OF KENYA MINISTRY OF HEALTH PHARMACY AND POISONS BOARD DRAFT GUIDELINE FOR IMPORTATION OF ORPHAN MEDICINAL SUBSTANCES IN KENYA

Technical matters: Traditional medicine: Delhi Declaration

Case scenarios: Patient Group Directions

REGULATION (EC) No.141/2000

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

DRAFT UGANDA STANDARD

Prescribing Policy: Homeopathic Preparations

Residual Solvents: FDA/ Regulatory Perspective

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

Essential Medicines. WHO

EUROPEAN PHARMACOPOEIA: TACKLING FUTURE CHALLENGES OF THE QUALITY OF MEDICINES TOGETHER

CHASTE TREE. Vitex agnus-castus L. (Lamiaceae) (McGuffin et al. 2000; USDA 1998) Source material(s): Fruit/Berry (Blumenthal 2000; Mills & Bone 2000)

Approved by the State Duma on December 17, 1998 Approved by the Federation Council on December 23, 1998

REGULATORY CHALLENGES IN SOUTH AFRICA

ANNEX III ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR TRADITIONAL MEDICINES

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE

COMMISSION DELEGATED REGULATION (EU).../... of XXX

Measuring Emissions as Part of a Regulatory Regime. Prof. Riccardo Polosa Professor of Internal Medicine and Convenor CEN TC437/WG4

Halal certification in Indonesia. How the approaching mandatory halal certification will affect food businesses. Felicia Frances

LAW OF THE KYRGYZ REPUBLIC ON FORTIFICATION OF BAKING FLOUR

RESOLUTION OF THE STATE GREAT KHURAL OF MONGOLIA. 11 October 2002 No: 68 Ulaanbaatar. Adoption of the Government Policy on Drugs

REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition

ISO IDF 177 INTERNATIONAL STANDARD. Dried skimmed milk Determination of vitamin D content using high-performance liquid chromatography

Public Assessment Report Scientific discussion. Ginsana, oral solution. Asp.no.:

Transcription:

State Pharmacopoeia of Ukraine WHO INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS 29.02 2.03 2012 Geneva, Executive Board Room Oleksandr Gryzodub Director of «Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines», Doctor of Chemical Sciences, professor 33 Astronomicheskaya, Kharkov, 61085 tel.+38 (057) 719-93-75, fax:+38 (057) 719-93-83 gryzodub@phukr.kharkov.ua

1. State Pharmacopoeia of Ukraine (SPU) SPU is being developed by the Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines; established by the order of the Ministry of Healthcare March 19, 1992. Pharmacopoeial Center is a public self-financing enterprise in the structure of the State Service of Ukraine on Medicinal Products (SSUMP), that endorsed the SPU. Principal tasks: elaboration and distribution of the SPU; establishment and distribution of Pharmacopoeial Reference Standards; implementation of the Professional Testing Scheme for medicine control laboratories; quality control of medicines; related scientific issues. The Pharmacopoeial Center is the largest scientific center for standardization and quality control of medicines in Ukraine 2

2. Pharmacopoeia referred to in national/ regional legislations Status of SPU in Ukraine is defined by the law About medicinal products ; Article 2 Definition of the terms thereof states: The State Pharmacopoeia of Ukraine (SPU) is a legal act that contains general requirements for medicinal products, pharmacopoeal chapters as well as medicine quality control procedures. 3

3. National/regional legislation includes reference to other Status of other Pharmacopoeias in Ukraine is not defined by law/de jure. When registering medicines in Ukraine, in case when related monographs are missing in the SPU, an application of standards of the European Pharmacopoeia is permitted firstly, and those of other pharmacopoeias secondarily (the BP, USP, JP). Available other Pharmacopoeias are used as textbooks/reference manuals. 4

4. Publication of latest edition The SPU is being developed in conformity with the Decree of the President of Ukraine within the Strategy of Integration of Ukraine into the European Community The SPU is published in Ukrainian and Russian languages. 5

5. Update frequency It was planned to update SPU biannually but update frequency depends on availability of finances Last 2 Supplements were published biannually Now we are preparing the Second edition of the SPU. Planned date of publication 2013 6

6. For which products does the pharmacopoeia provide specifications? APIs and excipients - widely used as ingredients, raw materials for drugs largely represented on the local pharmaceutical market - 326 Dosage forms from national and WHO List of vital drugs 74 Herbal products - traditionally used by local manufacturers - 104 Biologicals (immunoseras, insulins, interferons, etc) - 24 Monovaccines included in the National scheme of vaccination 26 Traditional preparations, prepared ex temporo - 5 7

7. Number of texts included in the pharmacopoeia! Methods of Analysis (physical, phisicochemical, biological, pharmaceutical technical procedures) - 211! Reagents more then 2500! Materials for Containers and Containers 24! General texts 37! General monographs - 16! General monographs on dosage forms - 26! Homeopathy - 4 8

8.1. Collaboration with and/or being part of a (different) national/regional pharmacopoeia According to the national concept of integration into the European Community the SPU is harmonized with the European Pharmacopoeia (Eur.Ph.) Since 1998 the Ukrainian Pharmacopoeial Center is an observer in the Eur. Ph. and received from it an approval to use the Eur. Ph. monographs for SPU development 9

8.2. Collaboration with the USP Since 2010 the Pharmacopoeial Center has got status of the voting delegate in the USP. Grant of Rights to Copy and Adapt the USP-NF (the Adopt/Adapt Agreement) between the administration of USP and the Pharmacopoeial Center (signed on June 2, 2010) permits usage of the monographs of USP-NF for elaboration of national monographs for finished dosage forms. Memorandum (signed on October 27, 2011) between the USP and the State Service of Ukraine on Medicinal Products Visiting scientist program 10

8.3. Collaboration with the State Pharmacopoeia of the Republic of Kazakhstan (SPRK) A number of the Ukrainian Pharmacopoeial Center (UPhC) staff are members of the Editorial Board of the SPRK. The UPhC participated in elaboration of a considerable part of general and specific monographs of the SPRK. 11

9. 1. Publication of harmonized pharmacopoeial texts within the pharmacopoeia SPU monographs are composed of two parts a European part (translation of the corresponding monograph of the Eur.Ph.) and a national one National part In addition, there are a number of purely national monographs in the SPU which reflect progress of the national science and experience in medicine standardization 12

9. 2. Publication of harmonized pharmacopoeial texts within the pharmacopoeia Pursuant to the Grant of Rights to Copy and Adapt the USP-NF contract in the Supplement 4 are included 7 harmonized monographs for finished dosage forms and now for the SPU 2-nd Edition have been already elaborated 11 draft monographs. For another 19 monographs only some specific tests from corresponding monograph of USP-NF are included. It reflects the specificity of the Ukrainian pharmaceutical market. Draft monographs are available on our website: www.sphu.org 13

10. Interaction with stakeholders, including regulators Requirements of the SPU are mandatory for all enterprises and institutions of Ukraine, irrespective of their ownership, manufacturing, storing, controlling and using drugs. Process of the SPU elaboration is based on the effective collaboration and permanent feedbacks with key national scientific organizations, manufacturers and competent regulators. 14

11. Strategy for the future of the SPU Principle task transformation of the Ukraine status from the observer of the European Pharmacopoeia Commission to a membership. Within this task our actual perspectives! Development and publication of the 2 nd Edition of the SPU.! Further development of the National System of SPU Reference Standards.! Strengthening of feedback with users through further development of the National Professional Testing Scheme (PTS). 15

11.1. Development of the 2 nd Edition SPU Revision of the monographs in the 2-nd edition (2012-2013) on the base of further harmonization with Eur.Ph. and USP (formulated preparations). Elaboration of new monographs. Priority: finished dosage forms, biologicals for human and veterinary use. Development of the national concept of standardization of compounded/unlicensed and homeopathic preparations. 16

11.2. Further development of the National System of SPU Reference Standards Further enlargement of the List of SPU Reference Standards. Now the list of SPU RS is about 450 items, including about 50 impurities and approximately 50 herbal RS. Further implementation of procedures of certification of working RS for national manufacturers Further harmonization of the SPU RS with RS of the Eur.Ph, USP, WHO and other pharmacopoeias According to the SPU conception, user may apply - at his choice RS of the Eur.Ph or those of the SPU. For formulated preparation monographs harmonized with the USP user may apply RS of the USP or those of the SPU. 17

11.3. Professional Testing Scheme feedback with SPU users Ukrainian Pharmacopoeial Center is an organizer of the National Professional Testing Schemes (PTS) and consider them as an effective feedback with SPU users. PTS give opportunities to determine actual metrological characteristics of different pharmacopoeial analytical methods in Ukraine. PTS give occasion to make changes and recommendations in the SPU, that are confirmed by largescale interlaboratory experiments. Till now 8 PTS rounds were already held with about 60 participants in every round. Now the 9 th round is holding. 18

Pharmacopoeias global future vision Vital necessity for more tight collaboration of all pharmacopoeias Acceleration of the procedures of international harmonization between world leading pharmacopoeias. Elaboration of the mechanisms of interchangeability and accessibility of pharmacopeial texts for regional pharmacopoeias and regulatory authorities. 19

20